ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ALNY
INSM (44) VTRS (57) UTHR (82) ROIV (44) ⌘ Pro Terminal →

Alnylam Pharmaceuticals Inc. (ALNY) — RQD Stock Rating Cockpit

$165.00 -5.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $163.15

Alnylam Pharmaceuticals Inc. (ALNY) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $23.28B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALNY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $165.00 (-5.17% 1D, market cap $23.28B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ALNY ranks #223 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALNY compare to INSM and VTRS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALNY carries a Roarable D+ (55/100 RQD), trailing P/E of 74.2x, gross margin of 81.8%, and ROIC of 21.3%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and VTRS (Viatris Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC -8.1%, cap $22.05B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALNY?
▼

Per ALNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178670), Alnylam Pharmaceuticals Inc. generated $3.71B in revenue (+65.2% YoY), $313.7M in net income, and $465.4M in free cash flow against $4.97B in total assets and $1.88B in total debt. Key quantitative strengths: Strong cash generator (82% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $163.15 (-1.12%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 12.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Cash (17)Whales (7)SEC (14)Macro (5)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-1.4% Base Target
$504 Bull$163 Base$127 Bear
📬 FREE ALNY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALNY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY ALNY SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($465.4M FCF) & 81.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)

Altman Z-Score 3.16 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (28.2) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
63
Grade C+$223.82+3.1% Next Q
Q2 (-2Q)
60
Grade C$230.71-1.7% Next Q
Q3 (-1Q)
58
Grade C$226.79-27.2% Next Q
Current
55
Grade D+$165.00-0.5% Hist 90D α
Trajectory: C+ (63) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALNY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, ALNY faces multiple-compression risk if 74.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 74x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($234.01) or 200D SMA ($283.63) invalidates the momentum regime and cuts Target Base ($162.77) toward Bear Floor ($126.96).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALNY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALNY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 55%NO 45%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
28.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.16>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $163$165.00H: $480
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (82% profit margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on ALNY

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (85)

21.3% ROIC with 81.8% gross margin and 2.00% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 3.16 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

19/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like ALNY
  • ✓Strong cash generator (82% profit margin)—profits are backed by real money, not accounting tricks.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Priced at 74x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALNY)

  • ✓Walkthrough of ALNY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.62%🛡️ HOLDING TREND SUPPORT
2026-11-02O $232.4H $232.4L $165.0C $165.0VOL 11.80M
RES: $245.6SUP: $162.2SMA50: $234.0SMA200: $283.6
$408.8$342.3$275.7$209.2$142.6RES $245.6SUP $162.2$165.02026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALNY Butterfly Map → + Track ALNY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
47.6%/yr Implied 5Y Growth

vs. +65.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALNY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALNY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALNY)

Health Care Rank #223 of 1016 ⚔️ INSM vs ALNY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALNY vs. INSM, VTRS, UTHR, ROIV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alnylam Pharmaceuticals Inc. (ALNY) ranks #223 by composite RQD confidence (55/100, grade D+) and #67 by equity capitalization ($23.28B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with ALNY at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALNY ACTIVE
Alnylam Pharmaceuticals Inc.
D+ 55/100 74.2x 81.8% 21.3% -5.17% $23.28B Benchmark Subject
INSM
Insmed Incorporated
D 44/100 — 79.7% -35.0% +0.89% $24.37B /insm-vs-alny →
VTRS
Viatris Inc.
D+ 57/100 — 35.2% -8.1% -0.86% $22.05B /vtrs-vs-alny →
UTHR
United Therapeutics Corporation
A- 82/100 19.1x 87.9% 20.1% +0.87% $25.46B /uthr-vs-alny →
ROIV
Roivant Sciences Ltd.
D 44/100 — — -14.0% -1.63% $27.10B /roiv-vs-alny →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001178670

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alnylam Pharmaceuticals Inc. (ALNY) reported GAAP revenue of $3.71B (+65.2% vs. FY2024 revenue of $2.25B , and +103.1% cumulative change since FY2023) , GAAP net income of $313.7M, operating cash flow of $524.1M, and free cash flow of $465.4M (+1192.7% YoY). On the balance sheet, ALNY closed FY2025 with $4.97B in total assets against $1.88B in total debt (Altman Z-Score: 3.16, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.71B $313.7M $524.1M $465.4M $4.97B $1.88B
FY2024 (FY) 2024-12-31 $2.25B -$278.2M -$8.3M -$42.6M $4.24B $1.88B
FY2023 (FY) 2023-12-31 $1.83B -$440.2M $104.2M $21.9M $12.81B $3.00B

3. ALNY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $165.00 (-5.17% 1D, market cap $23.28B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ALNY ranks #223 in composite RQD confidence.

How does ALNY compare to INSM and VTRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALNY carries a Roarable D+ (55/100 RQD), trailing P/E of 74.2x, gross margin of 81.8%, and ROIC of 21.3%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and VTRS (Viatris Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC -8.1%, cap $22.05B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALNY?

Per ALNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001178670), Alnylam Pharmaceuticals Inc. generated $3.71B in revenue (+65.2% YoY), $313.7M in net income, and $465.4M in free cash flow against $4.97B in total assets and $1.88B in total debt. Key quantitative strengths: Strong cash generator (82% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALNY trading relative to its 50-day, 200-day, and 52-week technical levels?

ALNY last traded at $165.00 (-5.17% on volume of 7,056,830 shares), positioning the stock -29.49% below its 50-day simple moving average ($234.01) and -41.83% below its 200-day simple moving average ($283.63). Across its 52-week range of $163.30 to $479.79, ALNY sits at the 0.5% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($144.37 to $185.63).

ALNY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALNY stock right now?

Alnylam Pharmaceuticals Inc. (ALNY) currently earns a Roarable Rating of D+ (Sell — SELL) with 55/100 RQD Confidence. Stretched risk/reward at 74x P/E (21% return on capital) under elevated 10-year interest-rate pressure.

What is ALNY's 12-month price target and RQD AI Jury consensus?

ALNY's 12-month base price target is $162.77 (range $126.96 to $503.78), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALNY RQD Cockpit ALNY 12M Forecast ALNY Earnings & Move ALNY Dividends & DRIP ALNY Insiders & 13F ALNY Whale Options ALNY Profit Sankey ALNY News & Why
ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALNY — Alnylam Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:13:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 55, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." Per the Roarable RQD rating, the five pillars score as follows:

  • Fundamental Cash Engine: 17 / 20. Supported by ROIC of 21.3% and a free cash flow yield of 2%. This is the strongest pillar and indicates that the business generates returns on invested capital, though the low FCF yield means investors are paying a high price relative to current cash generation.
  • Whale 13F Flow: 7 / 20. Reflects institutional accumulation and options positioning. A low score here suggests limited evidence of strong institutional conviction in the source data.
  • Insider Conviction: 12 / 20. Reflects SEC Form 4 and Congressional PTR cluster flow. A mid-range score indicates neither a clear insider buying signal nor a strong selling signal in the source data.
  • Macro Regime Fit: 5 / 20. Reflects beta of 1 and sector sensitivity. This is the weakest pillar and suggests limited alignment between the stock's profile and the current macro backdrop as captured by this rating.
  • Forensic Balance Sheet: 14 / 20. Supported by Altman Z of 3.16, Piotroski F of 8/9, and Debt/Equity of 2.22. The Altman and Piotroski readings are constructive, while the elevated leverage ratio is a counterweight.

For a prospective investor, the rating points to a profile where operating economics and balance-sheet metrics are comparatively better than market-facing signals. The price has declined 25.13% per the market data, with a 52-week range of $163.3 – $479.79. Valuation metrics are elevated per the market data: P/E (TTM) of 74.2, forward P/E of 62.3, and EV/EBITDA of 42.4. Those multiples imply that much of the future growth is already priced in, so the upside case depends on sustained earnings expansion, while the downside case is exposed to any slowdown. The rating's verdict is a Sell/Trim classification and should be read as the framework's assessment, not as personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
174$23.28B74.262.342.42.340%1$163.3 - $479.7921.3%

Business

Alnylam Pharmaceuticals Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the profile. Per the market data, the company reports an 81.8% gross margin, indicating high product-level economics. Source data does not specify its products, customers, or specific revenue model beyond the sector and industry classification.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$3713.9M$501.6M$313.7MN/A$465.4M$1657.2M$1879.7M
FY 2024$2248.2M$-176.9M$-278.2MN/A$-42.6M$966.4M$1877.8M
FY 2023$1828.3M$-282.2M$-440.2MN/A$21.9MN/A$2996.5M

Per the SEC financials, reported revenue grew from $1828.3M (FY 2023) to $3713.9M (FY 2025), with operating income turning positive in FY 2025 at $501.6M. Per the market data, the operating margin is 13.5% and net margin is 8.4%, with ROIC of 21.3%. Per the Roarable RQD rating, the forensic balance sheet shows an Altman Z-Score of 3.16, a Piotroski F-Score of 8/9, and Debt/Equity of 2.22. Debt was $1879.7M against cash of $1657.2M in FY 2025 per the SEC financials.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the feed contains six items, all tagged to ALNY:

  • RISK WATCH (RED): A Yahoo Finance item headlined that the stock "Looks Fully Priced Following Its 52% Fall."
  • MARKET WIRE (YELLOW): A Trefis item noting five straight red trading days with the stock down 14%.
  • CATALYST (GREEN): A ChartMill item framing the company as a decent value stock balancing undervaluation and growth.
  • MARKET WIRE (YELLOW): A Motley Fool comparison of Alnylam and Ionis as a "better bad-news buy."
  • MARKET WIRE (YELLOW): A Yahoo Finance item asking whether the RNAi franchise could earn an S&P 500 index entry.
  • MARKET WIRE (YELLOW): A Motley Fool item questioning why investors treat a solidly profitable company like a broken biotech.

Per the butterfly supply-chain graph, the supply chain is marked "NONE," with no butterfly links and no proprietary signals.

Open Questions

  • What are the company's specific revenue drivers and product lines behind the FY 2025 revenue increase to $3713.9M?
  • Why is EPS reported as N/A across all periods, and what is the basis for the EPS (TTM) of 2.34?
  • What is the composition of the $1879.7M debt, including maturity profile and interest burden?
  • Who are the institutional holders and insiders, and what are their recent position changes?
  • What analyst consensus, rating, or price targets exist for the stock?

ALNY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alnylam Pharmaceuticals Inc. (ALNY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALNY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALNY Bull vs. Bear Conversation Board — What's Your Call at $165.00?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALNY 🐻 50% BEARISH CONVICTION
1. Pick Your Side on ALNY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $187.92 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALNY (D+ • RQD 55/100) a Buy at $174.00?

Welcome to the ALNY (Alnylam Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (21.3% ROIC), while bears focus on valuation multiple compression (74.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $135.72 (-22.0%)
Spot @ $174.00

Pump the brakes on ALNY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALNY, but look at what you are paying: 74.2x trailing P/E with 81.8% gross margins. Unless Alnylam Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $208.80 (+20.0%)
Spot @ $174.00

ALNY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALNY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $174.00 (52-wk range $163.30 - $479.79), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%